ImMed Biotechnologies

ImMed Biotechnologies is a clinical-stage biotechnology company dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company leverages its proprietary multispecific antibody platform to design next-generation biologics that target multiple pathways simultaneously, aiming for superior efficacy over existing monotherapies. Its lead candidate, IMB-101, is a bispecific antibody targeting both IL-17 and IL-23, currently undergoing clinical evaluation for chronic inflammatory conditions. ImMed is headquartered in Suzhou, China, and maintains a robust pipeline of candidates targeting key cytokines and receptors involved in immune-mediated pathology. The firm is backed by prominent healthcare investors and focuses on addressing significant unmet needs in dermatology and rheumatology.